Table 1.

Selected ongoing venetoclax combination studies in B-cell lymphomas

Agent(s) combined with venetoclaxPhasePatients, nPatient populationNCT trial numberReference
CLL      
 Rituximab 1b 49 R/R NCT01682616 70  
 Bendamustine plus rituximab or obinutuzumab 1b 100* 1L and R/R NCT01671904 71  
 Obinutuzumab 1b 81 1L and R/R NCT01685892 72  
 Bendamustine → obinutuzumab 2 66 1L and R/R NCT02401503 54  
 Rituximab 3 391 R/R NCT02005471 clinicaltrials.gov 
 Obinutuzumab 3 445 1L NCT02242942 clinicaltrials.gov 
 Ibrutinib 2 78* 1L and R/R NCT02756897 clinicaltrials.gov 
 Ibrutinib, obinutuzumab 2 40* 1L del(17p) NCT02758665 clinicaltrials.gov 
 Ibrutinib, obinutuzumab 1b/2 68* 1L and R/R NCT02427451 clinicaltrials.gov 
NHL      
 Rituximab vs bendamustine/rituximab 2 164 R/R FL NCT02187861 58  
 Obinutuzumab 1 25* 1L FL NCT02877550 clinicaltrials.gov 
 Ibrutinib 2 24* 1L MCL NCT02471391 59  
 R-CHOP or O-CHOP 1b 248* 1L DLBCL NCT02055820 60  
 Dose-adjusted R-EPOCH 2 20* Richter syndrome NCT03054896 clinicaltrials.gov 
Agent(s) combined with venetoclaxPhasePatients, nPatient populationNCT trial numberReference
CLL      
 Rituximab 1b 49 R/R NCT01682616 70  
 Bendamustine plus rituximab or obinutuzumab 1b 100* 1L and R/R NCT01671904 71  
 Obinutuzumab 1b 81 1L and R/R NCT01685892 72  
 Bendamustine → obinutuzumab 2 66 1L and R/R NCT02401503 54  
 Rituximab 3 391 R/R NCT02005471 clinicaltrials.gov 
 Obinutuzumab 3 445 1L NCT02242942 clinicaltrials.gov 
 Ibrutinib 2 78* 1L and R/R NCT02756897 clinicaltrials.gov 
 Ibrutinib, obinutuzumab 2 40* 1L del(17p) NCT02758665 clinicaltrials.gov 
 Ibrutinib, obinutuzumab 1b/2 68* 1L and R/R NCT02427451 clinicaltrials.gov 
NHL      
 Rituximab vs bendamustine/rituximab 2 164 R/R FL NCT02187861 58  
 Obinutuzumab 1 25* 1L FL NCT02877550 clinicaltrials.gov 
 Ibrutinib 2 24* 1L MCL NCT02471391 59  
 R-CHOP or O-CHOP 1b 248* 1L DLBCL NCT02055820 60  
 Dose-adjusted R-EPOCH 2 20* Richter syndrome NCT03054896 clinicaltrials.gov 

1L, front line; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; EPOCH, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin; NCT, National Clinical Trial; O, obinutuzumab; R, rituximab; R/R, relapsed/refractory.

*

For actively accruing studies, the number listed is the planned total accrual.

[ViewLarge]
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal